844 related articles for article (PubMed ID: 32920850)
1. Real-World Patient Experience With Erenumab for the Preventive Treatment of Migraine.
Robblee J; Devick KL; Mendez N; Potter J; Slonaker J; Starling AJ
Headache; 2020 Oct; 60(9):2014-2025. PubMed ID: 32920850
[TBL] [Abstract][Full Text] [Related]
2. Long-term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study.
Barbanti P; Aurilia C; Cevoli S; Egeo G; Fofi L; Messina R; Salerno A; Torelli P; Albanese M; Carnevale A; Bono F; D'Amico D; Filippi M; Altamura C; Vernieri F;
Headache; 2021 Oct; 61(9):1351-1363. PubMed ID: 34309862
[TBL] [Abstract][Full Text] [Related]
3. Safety and Tolerability of 3 CGRP Monoclonal Antibodies in Practice: A Retrospective Cohort Study.
Alex A; Vaughn C; Rayhill M
Headache; 2020 Nov; 60(10):2454-2462. PubMed ID: 32969035
[TBL] [Abstract][Full Text] [Related]
4. Erenumab in the prevention of high-frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real-life study.
Barbanti P; Aurilia C; Egeo G; Fofi L; Cevoli S; Colombo B; Filippi M; Frediani F; Bono F; Grazzi L; Salerno A; Mercuri B; Carnevale A; Altamura C; Vernieri F
Headache; 2021 Feb; 61(2):363-372. PubMed ID: 33337544
[TBL] [Abstract][Full Text] [Related]
5. Real-Life Response to Erenumab in a Therapy-Resistant Case Series of Migraine Patients From the Province of Québec, Eastern Canada.
Eghtesadi M; Leroux E; Pagé G
Clin Drug Investig; 2021 Aug; 41(8):733-739. PubMed ID: 34287786
[TBL] [Abstract][Full Text] [Related]
6. Pooled retrospective analysis of 70 mg erenumab in episodic and chronic migraine: a two tertiary headache centers experience during clinical practice.
Storch P; Burow P; Möller B; Kraya T; Heintz S; Politz N; Naegel S
Acta Neurol Belg; 2022 Aug; 122(4):931-937. PubMed ID: 34406609
[TBL] [Abstract][Full Text] [Related]
7. Erenumab in Chronic Migraine: An Australian Experience.
Cheng S; Jenkins B; Limberg N; Hutton E
Headache; 2020 Nov; 60(10):2555-2562. PubMed ID: 32990364
[TBL] [Abstract][Full Text] [Related]
8. A prospective real-world analysis of erenumab in refractory chronic migraine.
Lambru G; Hill B; Murphy M; Tylova I; Andreou AP
J Headache Pain; 2020 Jun; 21(1):61. PubMed ID: 32487102
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study.
Reuter U; Goadsby PJ; Lanteri-Minet M; Wen S; Hours-Zesiger P; Ferrari MD; Klatt J
Lancet; 2018 Nov; 392(10161):2280-2287. PubMed ID: 30360965
[TBL] [Abstract][Full Text] [Related]
10. Real-world experience of erenumab in patients with chronic or episodic migraine in the UAE.
Alsaadi T; Noori S; Varakian R; Youssef S; Almadani A
BMC Neurol; 2022 Jun; 22(1):221. PubMed ID: 35710354
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of erenumab and onabotulinumtoxinA on acute medication usage and health care resource utilization as migraine prevention in the United States.
Tepper SJ; Fang J; Zhou L; Shen Y; Vo P; Abdrabboh A; Glassberg MB; Ferraris M
J Manag Care Spec Pharm; 2021 Sep; 27(9):1157-1170. PubMed ID: 33998825
[No Abstract] [Full Text] [Related]
12. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial.
Tepper S; Ashina M; Reuter U; Brandes JL; Doležil D; Silberstein S; Winner P; Leonardi D; Mikol D; Lenz R
Lancet Neurol; 2017 Jun; 16(6):425-434. PubMed ID: 28460892
[TBL] [Abstract][Full Text] [Related]
13. The Spectrum of Response to Erenumab in Patients With Episodic Migraine and Subgroup Analysis of Patients Achieving ≥50%, ≥75%, and 100% Response.
Broessner G; Reuter U; Bonner JH; Dodick DW; Hallström Y; Picard H; Zhang F; Lenz RA; Klatt J; Mikol DD
Headache; 2020 Oct; 60(9):2026-2040. PubMed ID: 32851644
[TBL] [Abstract][Full Text] [Related]
14. Early Use of Erenumab vs Nonspecific Oral Migraine Preventives: The APPRAISE Randomized Clinical Trial.
Pozo-Rosich P; Dolezil D; Paemeleire K; Stepien A; Stude P; Snellman J; Arkuszewski M; Stites T; Ritter S; Lopez Lopez C; Maca J; Ferraris M; Gil-Gouveia R
JAMA Neurol; 2024 May; 81(5):461-470. PubMed ID: 38526461
[TBL] [Abstract][Full Text] [Related]
15. Real-life assessment of erenumab in refractory chronic migraine with medication overuse headache.
Pensato U; Baraldi C; Favoni V; Cainazzo MM; Torelli P; Querzani P; Pascazio A; Mascarella D; Matteo E; Quintana S; Asioli GM; Cortelli P; Pierangeli G; Guerzoni S; Cevoli S
Neurol Sci; 2022 Feb; 43(2):1273-1280. PubMed ID: 34224026
[TBL] [Abstract][Full Text] [Related]
16. Multidimensional assessment of the effects of erenumab in chronic migraine patients with previous unsuccessful preventive treatments: a comprehensive real-world experience.
Russo A; Silvestro M; Scotto di Clemente F; Trojsi F; Bisecco A; Bonavita S; Tessitore A; Tedeschi G
J Headache Pain; 2020 Jun; 21(1):69. PubMed ID: 32517693
[TBL] [Abstract][Full Text] [Related]
17. Erenumab Efficacy on Comorbid Cluster Headache in Patients With Migraine: A Real-World Case Series.
Silvestro M; Tessitore A; Scotto di Clemente F; Tedeschi G; Russo A
Headache; 2020 Jun; 60(6):1187-1195. PubMed ID: 32359106
[TBL] [Abstract][Full Text] [Related]
18. Impact of a reimbursement policy change on treatment with erenumab in migraine - a real-world experience from Germany.
Hong JB; Lange KS; Fitzek M; Overeem LH; Triller P; Siebert A; Reuter U; Raffaelli B
J Headache Pain; 2023 Oct; 24(1):144. PubMed ID: 37899428
[TBL] [Abstract][Full Text] [Related]
19. Real-world long-term efficacy and safety of erenumab in adults with chronic migraine: a 52-week, single-center, prospective, observational study.
Cullum CK; Do TP; Ashina M; Bendtsen L; Hugger SS; Iljazi A; Gusatovic J; Snellman J; Lopez-Lopez C; Ashina H; Amin FM
J Headache Pain; 2022 Jun; 23(1):61. PubMed ID: 35655137
[TBL] [Abstract][Full Text] [Related]
20. Erenumab in highly therapy-refractory migraine patients: First German real-world evidence.
Scheffler A; Messel O; Wurthmann S; Nsaka M; Kleinschnitz C; Glas M; Naegel S; Holle D
J Headache Pain; 2020 Jul; 21(1):84. PubMed ID: 32620151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]